Eisai Inc.

This study tests whether adding perampanel (Fycompa) to current epilepsy medications can reduce seizures in children aged 1 month to 18 years. About 100 children with specific epilepsy syndromes or partial-onset seizures will receive the drug. The main goal is to see if at least …

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This study tests an investigational drug called lecanemab in people aged 55-80 who have early signs of Alzheimer's-related brain changes but no memory problems yet. The goal is to see if the drug can slow cognitive decline and reduce amyloid buildup over about 4 years. Around 140…

This study tests whether lecanemab can slow memory and thinking decline in people with early Alzheimer's disease. About 1,900 participants received either the drug or a placebo for 18 months, followed by an open-label extension where everyone can get lecanemab. The main goal is t…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This early-stage study tests a new drug (H3B-6545) combined with an existing drug (palbociclib) in women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. About 31 women who have already tried other treatmen…

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could delay cancer growth better than sunitinib alone. About 1,069 adults with …

This phase 2 trial is testing whether adding a new drug called E2814 to the existing Alzheimer's drug lecanemab can better slow the disease in people with early Alzheimer's. The study involves 105 participants and will measure changes in tau protein levels in spinal fluid and bra…

This program provides continued access to the seizure medication perampanel (Fycompa) for people who completed certain earlier studies and are still benefiting from the drug. It runs until the drug is commercially available in their country or no participants remain. Only those a…